News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

KemPharm, Inc. Expands ADHD Pipeline With Discovery of KP415


8/30/2011 9:58:44 AM

NORTH LIBERTY, Iowa, Aug. 30, 2011 (GLOBE NEWSWIRE) -- KemPharm, Inc. ("KemPharm") today announced it plans to initiate development of its recently identified lead compound KP415, a first-in-class prodrug of methylphenidate, which is a commonly used medication for the treatment of attention-deficit hyperactivity disorder (ADHD). KP415 was identified using KemPharm's Ligand Activated Therapy (LAT) approach. KP415 is the second product candidate in KemPharm's ADHD portfolio, which also includes KP106, a prodrug of d-amphetamine that has successfully completed a clinical proof-of-concept trial against Vyvanse®. KemPharm is actively seeking a pharmaceutical partner for late-stage clinical development and commercialization of its novel ADHD franchise.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES